Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland
Respiration · 2024
DOI: 10.1159/000539410 ↗Kurz gefasst
Leitlinie in der Zeitschrift Respiration, 2024. Verfasst von Ralf Otto-Knapp und 18 weiteren Autor:innen. Beteiligte Einrichtung: DZK German Central Committee against Tuberculosis e.V., Berlin, Germany. Hauptthemen laut MEDLINE: Antitubercular Agents, Extensively Drug-Resistant Tuberculosis, Rifampin, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB) in December 2022. The new recommendations and the latest study data made it necessary to update the existing guideline on the treatment of at least rifampicin-resistant TB (RR-TB) for the German-speaking countries, replacing the respective chapters of the treatment guidelines published in 2022. A shortened treatment of proven RR-TB and multidrug-resistant TB for at least 6 months using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Austria, Germany, and Switzerland under certain conditions considering the existing barriers for the implementation of the new treatment regimen. For the treatment of pre-extensively drug-resistant (pre-XDR-) TB, an individualized treatment for 18 months continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in selected pre-XDR-TB cases, provided that all prerequisites are met. The necessary requirements for using BPaLM and BPaL are presented in detail in this amendment to the consensus-based TB treatment guideline for adult patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DZK German Central Committee against Tuberculosis e.V., Berlin, Germany.
- Lung Hospital Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany.
- Division of Pneumology, Department of Pediatrics, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- National Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
- Department of Pneumology, University of Rostock, Rostock, Germany.
Zitieren
APA
Otto-Knapp, R., Bauer, T., Brinkmann, F., Feiterna-Sperling, C., Friesen, I., Geerdes-Fenge, H., Hartmann, P., Häcker, B., Heyckendorf, J., Kuhns, M., Lange, C., Maurer, F. P., Nienhaus, A., Priwitzer, M., Richter, E., Salzer, H. J. F., Schoch, O. D., Schönfeld, N., & Schaberg, T. (2024). Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. https://doi.org/10.1159/000539410
Vancouver
Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, et al. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. 2024. doi:10.1159/000539410
BibTeX
@article{OttoKnapp2024,
author = {Otto-Knapp, Ralf and Bauer, Torsten and Brinkmann, Folke and Feiterna-Sperling, Cornelia and Friesen, Inna and Geerdes-Fenge, Hilte and Hartmann, Pia and Häcker, Brit and Heyckendorf, Jan and Kuhns, Martin and Lange, Christoph and Maurer, Florian P and Nienhaus, Albert and Priwitzer, Martin and Richter, Elvira and Salzer, Helmut J F and Schoch, Otto D and Schönfeld, Nicolas and Schaberg, Tom},
title = {Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland},
journal = {Respiration},
year = {2024},
doi = {10.1159/000539410}
}
EUVIMED